Around the World

The recent UK parliamentary debate on medical cannabis under the new Labour administration has been a major disappointment for advocates and investors hoping for reform. Despite a chorus of voices from multiple parties calling for an overhaul of the UK’s outdated regulatory framework, the government has once again reverted to its well-worn stance, emphasizing the […]

The cannabis rescheduling debate in the United States has reached a critical juncture, marked by the recent appointment of Derek Maltz as interim administrator of the U.S. Drug Enforcement Administration (DEA). Maltz, a career DEA official and former chief of the New York Drug Enforcement Task Force, has expressed skepticism about the ongoing process to

The cannabis industry in the United States finds itself at a critical crossroads. While legislative progress continues to inch forward and the market matures, fundamental challenges like high taxation, overleveraged businesses, and investor skepticism threaten to hinder growth. As the industry gathers for MJBizCon, it’s an opportune moment to discuss the pressing realities and untapped

As cannabis policies evolve across Europe, a new era of collaboration is shaping the continent’s approach to regulating non-medical cannabis. In Berlin, ministerial representatives, experts, and civil society stakeholders from countries such as Luxembourg, Malta, the Netherlands, Czech Republic, Switzerland, and Germany convened to discuss the future of cannabis regulation. Hosted by Germany’s Federal Commissioner

As Poland inches closer to a landmark decision on cannabis policy, the country finds itself navigating two transformative paths: decriminalization of recreational cannabis and scaling its booming medical cannabis market. With a proposal to decriminalize cannabis possession and cultivation awaiting Prime Minister Donald Tusk’s response, and medical cannabis imports soaring to unprecedented levels, Poland’s cannabis

When the UK rescheduled cannabis six years ago, it marked a historic turning point—a beacon of hope for patients in need and a gateway for cannabis entrepreneurs. Despite this milestone, the journey toward effective patient access remains fraught with obstacles, particularly within the public sector. A recent report from the Cannabis Industry Council (CIC) highlights

Cannabis startups are springing up worldwide, driven by increasing legalization and shifting public attitudes. However, the industry’s complex regulatory landscape and unique challenges make sustainable scaling a daunting task. Companies like MedMen and Eaze offer valuable lessons on the potential pitfalls and opportunities in this space. Here’s how startups can learn from their experiences to

Spain is making gradual progress in regulating medical cannabis, with the Ministry of Health moving forward with a Real Decreto (Royal Decree) to establish a framework for its therapeutic use. However, the approach remains conservative, especially compared to other European nations that are advancing both medicinal and recreational cannabis regulations. What the Royal Decree Proposes

The cannabis landscape in Czechia is on the verge of a significant transformation, opening up fresh opportunities for cannabis founders. The recent proposal by the Czech Ministry of Justice could reshape the industry, making it legal for adults over 21 to grow up to three cannabis plants and possess up to 50 grams of dried